MedTrace Logo

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-06-18

No results posted yet for this study

Summary

The aim of this study is to determine the impact of systemic immunosuppression on sustained antibody COVID-19 concentrations in patients with IBD who received a COVID-19 vaccine.

Conditions

  • Inflammatory Bowel Diseases

Interventions

BIOLOGICAL

COVID-19 Vaccine

Three-dose mRNA COVID-19 vaccine per standard of care

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • GI Alliance

    lead OTHER

Principal Investigators

  • Tim Ritter, MD · GI Alliance

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-05
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05014555 on ClinicalTrials.gov